Treatment of thyrotoxicosis

Journal of Nuclear Medicine

Volumn 48, Issue 3, 2007, Pages 379-389

  Iagaru, Andrei ^a   McDougall, I Ross ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

131I treatment; Antithyroid medications; Graves' disease; Thyroidectomy; Thyrotoxicosis; Toxic nodular goiter

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTITHYROID AGENT; CARBIMAZOLE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; IODINE 131; LITHIUM; PREDNISONE; PROPYLTHIOURACIL; RADIOISOTOPE; THIAMAZOLE; RADIOACTIVE IODINE;

ADJUVANT THERAPY; AGRANULOCYTOSIS; CHOLESTASIS; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; ENDOCRINE OPHTHALMOPATHY; FEVER; GENERAL ANESTHESIA; GRAVES DISEASE; HISTORY OF MEDICINE; HUMAN; HYPOTHYROIDISM; INCIDENCE; LIVER FAILURE; LIVER NECROSIS; MACULOPAPULAR RASH; NAUSEA; PREGNANCY; PRIORITY JOURNAL; RADIATION DOSE; RENAL REPLACEMENT THERAPY; REVIEW; SORE THROAT; TASTE DISORDER; THYROID CANCER; THYROIDECTOMY; THYROIDITIS; THYROTOXICOSIS; TOXIC GOITER; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URTICARIA; PATIENT EDUCATION;

ANTITHYROID AGENTS; GRAVES DISEASE; HUMANS; IODINE RADIOISOTOPES; PATIENT EDUCATION; RADIOTHERAPY DOSAGE; THYROIDECTOMY; THYROTOXICOSIS; TREATMENT FAILURE;

EID: 34247214645     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (136)

1. Tunbridge WM, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: the Whickham Survey. Clin Endocrinol (Oxf). 1977;7:481-493.
2. Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf). 1995;43:55-68.
3. Franklyn J. Thyrotoxicosis. Clin Med. 2003;3:11-15.
4. Vassart G. Activating mutations of the TSH receptor. Thyroid. 2004;14:86-87.
5. Solomon B, Glinoer D, Lagasse R, Wartofsky L. Current trends in the management of Graves' disease. J Clin Endocrinol Metab. 1990;70:1518-1524.
6. Wartofsky L, Glinoer D, Solomon B, et al. Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid. 1991;1:129-135.
7. Krassas GE, Laron Z. A questionnaire survey concerning the most favourable treatment for Graves' disease in children and adolescents. Eur J Endocrinol. 2004;151:155-156.
8. Kaushal K, Bhattacharyya A, Gibson CM, Varghese B, Davis JR. Adequacy of information delivered to patients during consultation for thyrotoxicosis. Clin Endocrinol (Oxf). 2004;61:778-779.
9. Cunningham C, Lyons D, O'Neill D. Apathetic thyrotoxicosis [abstract]. Ir Med J. 1997;90:155.
10. Ghobrial MW, Ruby EB. Coma and thyroid storm in apathetic thyrotoxicosis. South Med J. 2002;95:552-554.
11. Ross DS. Syndromes of thyrotoxicosis with low radioactive iodine uptake. Endocrinol Metab Clin North Am. 1998;27:169-185.
12. Klonecke A, Petersen MM, McDougall IR. Thyrotoxicosis with low thyroidal uptake of radioiodine. Semin Nucl Med. 1990;20:364-366.
13. Parmar MS, Sturge C. Recurrent hamburger thyrotoxicosis. CMAJ. 2003;169:415-417.
14. Sinclair D. Clinical and laboratory aspects of thyroid autoantibodies. Ann Clin Biochem. 2006;43:173-183.
15. Drexhage HA. Are there more than antibodies to the thyroid-stimulating hormone receptor that meet the eye in Graves' disease? Endocrinology. 2006;147:9-12.
16. Shin JI, Park JM, Lee JS, Kim DH, Jeong HJ. Development of Graves' disease during cyclosporin treatment for severe Henoch-Schonlein nephritis. Nephrol Dial Transplant. 2005;20:2014-2015.
17. Abraham P, Avenell A, Park CM, Watson WA, Bevan JS. A systematic review of drug therapy for Graves' hyperthyroidism. Eur J Endocrinol. 2005;153:489-498.
18. Bartalena L, Tanda ML, Bogazzi F, Piantanida E, Lai A, Martino E. An update on the pharmacological management of hyperthyroidism due to Graves' disease. Expert Opin Pharmacother. 2005;6:851-861.
19. Cooper DS. Antithyroid drugs. N Engl J Med. 2005;352:905-917.
20. Pearce EN, Braverman LE. Hyperthyroidism: advantages and disadvantages of medical therapy. Surg Clin North Am. 2004;84:833-847.
21. Zweig SB, Schlosser JR, Thomas SA, Levy CJ, Fleckman AM. Rectal administration of propylthiouracil in suppository form in patients with thyrotoxicosis and critical illness: case report and review of literature. Endocr Pract. 2006;12:43-47.
22. Hodak SP, Huang C, Clarke D, Burman KD, Jonklaas J, Janicic-Kharic N. Intravenous methimazole in the treatment of refractory hyperthyroidism. Thyroid. 2006;16:691-695.
23. McDermott MT, Kidd GS, Dodson LE Jr, Hofeldt FD. Radioiodine-induced thyroid storm: case report and literature review. Am J Med. 1983;75:353-359.
24. Hayek A. Thyroid storm following radioiodine for thyrotoxicosis. J Pediatr. 1978;93:978-980.
25. 131I therapy for hyperthyroidism in patients not pretreated with antithyroid drugs. Neth J Med. 1999;55:215-221.
26. Imseis RE, Vanmiddlesworth L, Massie JD, Bush AJ, Vanmiddlesworth NR. Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism. J Clin Endocrinol Metab. 1998;83:685-687.
27. Santos RB, Romaldini JH, Ward LS. Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves' disease. Thyroid. 2004;14:525-530.
28. 131I with pre-treatment with carbimazole for thyrotoxicosis: the Gateshead Protocol. Nucl Med Commun. 2004;25:675-682.
29. Walter MA, Christ-Crain M, Schindler C, Muller-Brand J, Muller B. Outcome of radioiodine therapy without, on or 3 days off carbimazole: a prospective interventional three-group comparison. Eur J Nucl Med Mol Imaging. 2006;33:730-737.
30. Weaver JU, Razvi S. Dose of anti-thyroid drugs can effect remission in Grave's disease [comment]. Endocr J. 2005;52:159.
31. Lal G, Ituarte P, Kebebew E, Siperstein A, Duh QY, Clark OH. Should total thyroidectomy become the preferred procedure for surgical management of Graves' disease? Thyroid. 2005;15:569-574.
32. England RJ, Kamath MB, Jabreel A, Dunne G, Atkin SL. How we do it: surgery should be considered equally with I131 and thionamide treatment as first-line therapy for thyrotoxicosis. Clin Otolaryngol. 2006;31:160-162.
33. Bhansali SK, Chandalia HB. Thyrotoxicosis: surgical management in the era of evidence-based medicine - experience in western India with 752 cases. Asian J Surg. 2002;25:291-299.
34. Gurleyik E, Pehlivan M, Gokpinar I. Surgery is the procedure of choice for the treatment of patients with toxic adenoma in an endemic goitre area. Acta Chir Belg. 2005;105:373-377.
35. Kang AS, Grant CS, Thompson GB, van Heerden JA. Current treatment of nodular goiter with hyperthyroidism (Plummer's disease): surgery versus radioiodine. Surgery. 2002;132:916-923.
36. Perros P, Kendall-Taylor P, Neoh C, Frewin S, Dickinson J. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves' ophthalmopathy. J Clin Endocrinol Metab. 2005;90:5321-5323.
37. Hertz S, Roberts A. Application of radioactive iodine in therapy of Graves' disease [abstract]. J Clin Invest. 1942;21:624.
38. Hamilton J, Lawrence JH. Recent clinical developments in the therapeutic application of radio-phosphorus and radio-iodine. J Clin Invest. 1942;624:1942.
39. 131I in treatment of Graves' disease. J R Soc Med. 1985;78:197-202.
40. Hoskin PJ, Spathis GS, McCready VR, Cosgrove DO, Harmer CL. Low-dose radioiodine given six-monthly in Graves' disease. J R Soc Med. 1985;78:893-898.
41. Kalinyak JE, McDougall IR. How should the dose of iodine-131 be determined in the treatment of Graves' hyperthyroidism? J Clin Endocrinol Metab. 2003;88:975-977.
42. 131I therapy for Graves' disease. Clin Endocrinol (Oxf). 1988;28:487-496.
43. Von Hofe SE, Dorfman SG, Carretta RF, Young RL. The increasing incidence of hypothyroidism within one year after radioiodine therapy for toxic diffuse goiter. J Nucl Med. 1978;19:180-184.
44. Ratcliffe GE, Fogelman I, Maisey MN. The evaluation of radioiodine therapy for thyroid patients using a fixed-dose regime. Br J Radiol. 1986;59:1105-1107.
45. Kendall-Taylor P, Keir MJ, Ross WM. Ablative radioiodine therapy for hyperthyroidism: long term follow up study. Br Med J (Clin Res Ed). 1984;289:361-363.
46. Alexander E, Larsen PR. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab. 2002;87:1073-1077.
47. McDougall IR, Greg WR. Combined carbimazole-131-I treatment for thyrotoxicosis. Scott Med J. 1972;17:57-61.
48. Rapoport B, Caplan R, DeGroot LJ. Low-dose sodium iodide I 131 therapy in Graves disease. JAMA. 1973;224:1610-1613.
49. Grosso M, Traino A, Boni G, et al. Comparison of different thyroid committed doses in radioiodine therapy for Graves' hyperthyroidism. Cancer Biother Radiopharm. 2005;20:218-223.
50. Howarth D, Epstein M, Lan L, Tan P, Booker J. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study. Eur J Nucl Med. 2001;28:1489-1495.
51. Tsuruta M, Nagayama Y, Yokoyama N, Izumi M, Nagataki S. Long-term follow-up studies on iodine-131 treatment of hyperthyroid Graves' disease based on the measurement of thyroid volume by ultrasonography. Ann Nucl Med. 1993;7:193-197.
52. Catargi B, Leprat F, Guyot M, Valli N, Ducassou D, Tabarin A. Optimized radioiodine therapy of Graves' disease: analysis of the delivered dose and of other possible factors affecting outcome. Eur J Endocrinol. 1999;141:117-121.
53. Bajnok L, Mezosi E, Nagy E, et al. Calculation of the radioiodine dose for the treatment of Graves' hyperthyroidism: is more than seven-thousand rad target dose necessary? Thyroid. 1999;9:865-869.
54. 131I therapy: a speculative paper. Nucl Med Commun. 2006;27:439-446.
55. 131I. Phys Med Biol. 2005;50:2181-2191.
56. Haase A, Bahre M, Lauer I, Meller B, Richter E. Radioiodine therapy in Graves' hyperthyroidism: determination of individual optimum target dose. Exp Clin Endocrinol Diabetes. 2000;108:133-137.
57. McDougall IR, Greig WR, Gillespie FC. Iodine-125 therapy for thyrotoxicosis: background and evaluation in 148 patients. Strahlentherapie (Sonderb). 1972;72:243-252.
58. Erem C, Kandemir N, Hacihasanoglu A, Ersoz HO, Ukinc K, Kocak M. Radioiodine treatment of hyperthyroidism: prognostic factors affecting outcome. Endocrine. 2004;25:55-60.
59. Cowan RJ, Ball JD, Watson NE. Efficacy of the four-hour radioiodine uptake determination prior to radioiodine therapy for hyperthyroidism [letter]. J Nucl Med. 1986;27:309.
60. Vemulakonda US, Atkins FB, Ziessman HA. Therapy dose calculation in Graves' disease using early I-123 uptake measurements. Clin Nucl Med. 1996;21:102-105.
61. Ibarra JD Jr, Thompson JQ, Alexander JS, Petrany Z. Radioiodine tracer tests in the evaluation of thyroid function: results of 6-hour and 24-hour uptake determinations in 357 patients. Am J Med Sci. 1960;239:140-143.
62. Greer MA. Correlation of the 24-hour radioiodine uptake of the human thyroid gland with the six- and eight-hour up-takes and the accumulation gradient. J Clin Invest. 1951;30:301-304.
63. Kinuya S, Michigishi T, Nakajima K, et al. Failure of radioiodine treatment in Graves' disease intentionally caused by a patient: suspected Munchausen syndrome. Ann Nucl Med. 2004;18:631-632.
64. Vidal-Trecan GM, Stahl JE, Eckman MH. Radioiodine or surgery for toxic thyroid adenoma: dissecting an important decision - a cost-effectiveness analysis. Thyroid. 2004;14:933-945.
65. Fumarola A, Sciacchitano S, Danese D, Andreoli M. The autonomous nodule: clinical aspects [in Italian]. Minerva Endocrinol. 1993;18:147-154.
66. Blum M, Shenkman L, Hollander CS. The autonomous nodule of the thyroid: correlation of patient age, nodule size and functional status. Am J Med Sci. 1975;269:43-50.
67. Blum M, Nocero MA Jr. Spontaneous resolution of a euthyroid autonomous nodule of the thyroid. Am J Med Sci. 1972;264:49-54.
68. Ratcliffe GE, Cooke S, Fogelman I, Maisey MN. Radioiodine treatment of solitary functioning thyroid nodules. Br J Radiol. 1986;59:385-387.
69. Sharma R, Bhatnagar A, Mondal A, Kashyap R, Khanna CM. Efficacy of standard ten millicurie dose of radio-iodine in management of autonomously functioning toxic thyroid nodules. J Assoc Physicians India. 1995;43:167-169, 172.
70. Huysmans DA, Corstens FH, Kloppenborg PW. Long-term follow-up in toxic solitary autonomous thyroid nodules treated with radioactive iodine. J Nucl Med. 1991;32:27-30.
71. Clerc J, Dagousset F, Izembart M, et al. Radioiodine therapy of the autonomous thyroid nodule in patients with or without visible extranodular activity. J Nucl Med. 1995;36:217-223.
72. Ceccarelli C, Bencivelli W, Vitti P, Grasso L, Pinchera A. Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years' retrospective study. Clin Endocrinol (Oxf). 2005;62:331-335.
73. Reiners C, Schneider P. Radioiodine therapy of thyroid autonomy. Eur J Nucl Med Mol Imaging. 2002;29(suppl 2):S471-S478.
74. Estour B, Millot L, Vergely N, et al. Efficacy of low doses of radioiodine in the treatment of autonomous thyroid nodules: importance of dose/area ratio. Thyroid. 1997;7:357-361.
75. Huysmans DA, Hermus AR, Corstens FH, Kloppenborg PW. Long-term results of two schedules of radioiodine treatment for toxic multinodular goitre. Eur J Nucl Med. 1993;20:1056-1062.
76. Reinhardt MJ, Biermann K, Wissmeyer M, et al. Dose selection for radioiodine therapy of borderline hyperthyroid patients according to thyroid uptake of (99m)Tc-pertechnetate: applicability to unifocal thyroid autonomy? Eur J Nucl Med Mol Imaging. 2006;33:608-612.
77. 131I or surgical treatment for toxic thyroid adenoma. Ann Intern Med. 1978;89:85-90.
78. Peterson ME, Graves TK, Gamble DA. Triiodothyronine (T3) suppression test: an aid in the diagnosis of mild hyperthyroidism in cats. J Vet Intern Med. 1990;4:233-238.
79. Pacella CM, Bizzarri G, Spiezia S, et al. Thyroid tissue: US-guided percutaneous laser thermal ablation. Radiology. 2004;232:272-280.
80. Larijani B, Pajouhi M, Ghanaati H, et al. Treatment of hyperfunctioning thyroid nodules by percutaneous ethanol injection. BMC Endocr Disord. 2002;2:3.
81. Tarantino L, Giorgio A, Mariniello N, et al. Percutaneous ethanol injection of large autonomous hyperfunctioning thyroid nodules. Radiology. 2000;214:143-148.
82. Mauz PS, Maassen MM, Braun B, Brosch S. How safe is percutaneous ethanol injection for treatment of thyroid nodule? Report of a case of severe toxic necrosis of the larynx and adjacent skin. Acta Otolaryngol. 2004;124:1226-1230.
83. Zingrillo M, Modoni S, Conte M, Frusciante V, Trischitta V. Percutaneous ethanol injection plus radioiodine versus radioiodine alone in the treatment of large toxic thyroid nodules. J Nucl Med. 2003;44:207-210.
84. Giovanella L, De Palma D, Ceriani L, et al. Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach: clinical results [in Italian]. Radiol Med (Torino). 2000;100:480-483.
85. Nygaard B, Hegedus L, Ulriksen P, Nielsen KG, Hansen JM. Radioiodine therapy for multinodular toxic goiter. Arch Intern Med. 1999;159:1364-1368.
86. Duick DS, Baskin HJ. Utility of recombinant human thyrotropin for augmentation of radioiodine uptake and treatment of nontoxic and toxic multinodular goiters. Endocr Pract. 2003;9:204-209.
87. Cohen O, Ilany J, Hoffman C, et al. Low-dose recombinant human thyrotropin-aided radioiodine treatment of large, multinodular goiters in elderly patients. Eur J Endocrinol. 2006;154:243-252.
88. Rubio IG, Perone BH, Silva MN, Knobel M, Medeiros-Neto G. Human recombinant TSH preceding a therapeutic dose of radioiodine for multinodular goiters has no significant effect in the surge of TSH-receptor and TPO antibodies. Thyroid. 2005;15:134-139.
89. Kadmon PM, Noto RB, Boney CM, Goodwin G, Gruppuso PA. Thyroid storm in a child following radioactive iodine (RAI) therapy: a consequence of RAI versus withdrawal of antithyroid medication. J Clin Endocrinol Metab. 2001;86:1865-1867.
90. Singer RB. Long-term comparative mortality in hyperthyroid patients treated with radio-iodine: a cohort study in England. J Insur Med. 2001;33:133-137.
91. Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P. Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med. 1998;338:712-718.
92. Ron E, Doody MM, Becker DV, et al. Cancer mortality following treatment for adult hyperthyroidism: Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA. 1998;280:347-355.
93. Ayala C, Navarro E, Rodriguez JR, Silva H, Venegas E, Astorga R. Conception after iodine-131 therapy for differentiated thyroid cancer. Thyroid. 1998;8:1009-1011.
94. Schlumberger M, De Vathaire F, Ceccarelli C, et al. Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J Nucl Med. 1996;37:606-612.
95. Bogazzi F, Bartalena L, Brogioni S, et al. Comparison of radioiodine with radioiodine plus lithium in the treatment of Graves' hyperthyroidism. J Clin Endocrinol Metab. 1999;84:499-503.
96. Cappelen T, Unhjem JF, Amundsen AL, Kravdal G, Folling I. Radiation exposure to family members of patients with thyrotoxicosis treated with iodine-131. Eur J Nucl Med Mol Imaging. 2006;33:81-86.
97. 131I. Radiat Prot Dosimetry. 2006;118:22-27.
98. Peterson ME. Radioiodine treatment of hyperthyroidism. Clin Tech Small Anim Pract. 2006;21:34-39.
99. Sinzinger H, Aiginger P, Neumann I, Havlik E. Radiation alarm at an airport after radioiodine therapy. Nucl Med Commun. 2005;26:67-68.
100. Gangopadhyay KK, Sundram F, De P. Triggering radiation alarms after radioiodine treatment. BMJ. 2006;333:293-294.
101. Hung W, Sarlis NJ. Autoimmune and non-autoimmune hyperthyroidism in pediatric patients: a review and personal commentary on management. Pediatr Endocrinol Rev. 2004;2:21-38.
102. Wiersinga WM. Thyroid associated ophthalmopathy: pediatric and endocrine aspects. Pediatr Endocrinol Rev. 2004;1(suppl 3):513-517.
103. Kubo T, Shimizu J, Furujo M, et al. An infant case of Graves' disease with ophthalmopathy. Endocr J. 2005;52:647-650.
104. Rivkees SA, Sklar C, Freemark M. Clinical review 99: the management of Graves' disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab. 1998;83:3767-3776.
105. Birrell G, Cheetham T. Juvenile thyrotoxicosis: can we do better? Arch Dis Child. 2004;89:745-750.
106. Segni M, Gorman CA. The aftermath of childhood hyperthyroidism. J Pediatr Endocrinol Metab. 2001;14(suppl 5):1277-1282.
107. Barrio R, Lopez-Capape M, Martinez-Badas I, Carrillo A, Moreno JC, Alonso M. Graves' disease in children and adolescents: response to long-term treatment. Acta Paediatr. 2005;94:1583-1589.
108. Rivkees SA. The management of hyperthyroidism in children with emphasis on the use of radioactive iodine. Pediatr Endocrinol Rev. 2003;1(suppl 2):212-221.
109. Rivkees S. Radioactive iodine use in childhood Graves' disease: time to wake up and smell the I-131. J Clin Endocrinol Metab. 2004;89:4227-4228.
110. Freitas JE, Swanson DP, Gross MD, Sisson JC. Iodine-131: optimal therapy for hyperthyroidism in children and adolescents? J Nucl Med. 1979;20:847-850.
111. Krassas GE. Treatment of juvenile Graves' disease and its ophthalmic complication: the 'European way.' Eur J Endocrinol. 2004;150:407-414.
112. Read CH Jr, Tansey MJ, Menda Y. A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves' patients. J Clin Endocrinol Metab. 2004;89:4229-4233.
113. Rahman MA, Birrell G, Stewart H, Lucraft H, Cheetham TD. Successful radioiodine treatment in a 3 year old child with Graves' disease following antithyroid medication induced neutropenia. Arch Dis Child. 2003;88:158-159.
114. Chen YT, Khoo DH. Thyroid diseases in pregnancy. Ann Acad Med Singapore. 2002;31:296-302.
115. Perros P. Thyrotoxicosis and pregnancy. PLoS Med. 2005;2:e370.
116. Cho YY, Shon HS, Yoon HD. Management of a pregnant patient with Graves' disease complicated by propylthiouracil induced agranulocytosis. Korean J Intern Med. 2005;20:335-338.
117. Barbero P, Ricagni C, Mercado G, Bronberg R, Torrado M. Choanal atresia associated with prenatal methimazole exposure: three new patients. Am J Med Genet A. 2004;129:83-86.
118. Foulds N, Walpole I, Elmslie F, Mansour S. Carbimazole embryopathy: an emerging phenotype. Am J Med Genet A. 2005;132:130-135.
119. Luton D, Le Gac I, Vuillard E, et al. Management of Graves' disease during pregnancy: the key role of fetal thyroid gland monitoring. J Clin Endocrinol Metab. 2005;90:6093-6098.
120. Berg GE, Nystrom EH, Jacobsson L, et al. Radioiodine treatment of hyperthyroidism in a pregnant women. J Nucl Med. 1998;39:357-361.
121. McDougall IR. Management of Thyroid Cancer and Related Nodular Disease. London, England: Springer; 2006.
122. 131I therapy for hyperthyroidism in the first trimester of pregnancy. J Nucl Med. 1976;17:146-149.
123. Berlin L. Iodine-131 and the pregnant patient. AJR. 2001;176:869-871.
124. Cawood T, Moriarty P, O'Shea D. Recent developments in thyroid eye disease. BMJ. 2004;329:385-390.
125. Wiersinga WM. The philosophy of Graves' ophthalmopathy. Orbit. 2005;24:165-171.
126. Bartalena L, Marcocci C, Tanda ML, et al. An update on medical management of Graves' ophthalmopathy. J Endocrinol Invest. 2005;28:469-478.
127. Gwinup G, Elias AN, Ascher MS. Effect on exophthalmos of various methods of treatment of Graves' disease. JAMA. 1982;247:2135-2138.
128. Sridama V, DeGroot LJ. Treatment of Graves' disease and the course of ophthalmopathy. Am J Med. 1989;87:70-73.
129. Tallstedt L, Lundell G, Torring O, et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med. 1992;326:1733-1738.
130. Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med. 1998;338:73-78.
131. Holm IA, Manson JE, Michels KB, Alexander EK, Willett WC, Utiger RD. Smoking and other lifestyle factors and the risk of Graves' hyperthyroidism. Arch Intern Med. 2005;165:1606-1611.
132. Krassas GE, Wiersinga W. Smoking and autoimmune thyroid disease: the plot thickens. Eur J Endocrinol. 2006;154:777-780.
133. Gorman CA. Temporal relationship between onset of Graves' ophthalmopathy and diagnosis of thyrotoxicosis. Mayo Clin Proc. 1983;58:515-519.
134. Marcocci C, Bartalena L, Bogazzi F, Panicucci M, Pinchera A. Studies on the occurrence of ophthalmopathy in Graves' disease. Acta Endocrinol (Copenh). 1989;120:473-478.
135. Holst JP, Burman KD, Atkins F, Ulmans JG, Jonklaas J. Radioiodine therapy for thyroid cancer and hyperthyroidism in patients with end-stage renal disease on hemodialysis. Thyroid. 2005;15:1321-1331.
136. Mello AM, Isaacs R, Petersen J, Kronenberger S, McDougall IR. Management of thyroid papillary carcinoma with radioiodine in a patient with end stage renal disease on hemodialysis. Clin Nucl Med. 1994;19:776-781.